Literature DB >> 25480498

Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator.

Seok Jin Kim1, Mineui Hong2, In-Gu Do2, Seung Ho Lee3, Kyung Ju Ryu4, Hae Yong Yoo5, Jung Yong Hong6, Young Hyeh Ko2, Won Seog Kim7.   

Abstract

Entities:  

Keywords:  extranodal NK/T-cell lymphoma; prognosis; serum; survivin; vascular endothelial growth factor

Mesh：

Substances：

Year:  2014        PMID： 25480498      PMCID： PMC4349290          DOI： 10.3324/haematol.2014.116087

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.

Authors:  Seok Jin Kim; Kihyun Kim; Byung Soo Kim; Chul Yong Kim; Cheolwon Suh; Jooryung Huh; Sang-Wook Lee; Jin Seok Kim; Jaeho Cho; Gyeong-Won Lee; Ki Mun Kang; Hyeon Seok Eom; Hong Ryull Pyo; Yong Chan Ahn; Young Hyeh Ko; Won Seog Kim
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

2.  SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.

Authors:  Yok-Lam Kwong; Won Seog Kim; Soon Thye Lim; Seok Jin Kim; Tiffany Tang; Eric Tse; Anskar Y H Leung; Chor-Sang Chim
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113

3.  Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma.

Authors:  T Krejsgaard; C S Vetter-Kauczok; A Woetmann; P Lovato; T Labuda; K W Eriksen; Q Zhang; J C Becker; N Ødum
Journal:  Leukemia       Date:  2006-08-17       Impact factor: 11.528

4.  Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.

Authors:  Siok-Bian Ng; Viknesvaran Selvarajan; Gaofeng Huang; Jianbiao Zhou; Andrew L Feldman; Mark Law; Yok-Lam Kwong; Norio Shimizu; Yoshitoyo Kagami; Katsuyuki Aozasa; Manuel Salto-Tellez; Wee-Joo Chng
Journal:  J Pathol       Date:  2011-01-05       Impact factor: 7.996

Review 5.  Survivin, cancer networks and pathway-directed drug discovery.

Authors:  Dario C Altieri
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

Review 6.  International analysis of the frequency and outcomes of NK/T-cell lymphomas.

Authors:  Basem M William; James O Armitage
Journal:  Best Pract Res Clin Haematol       Date:  2013-05-24       Impact factor: 3.020

Review 7.  Molecular underpinning of extranodal NK/T-cell lymphoma.

Authors:  Yenlin Huang; Laurence de Leval; Philippe Gaulard
Journal:  Best Pract Res Clin Haematol       Date:  2013-05-23       Impact factor: 3.020

8.  Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma.

Authors:  Hyo Song Kim; Kyung Hee Kim; Kyoung Ha Kim; Myung Hee Chang; Sang Hoon Ji; Do Hyoung Lim; Kihyun Kim; Seok Jin Kim; Younghyeh Ko; Chang-Seok Ki; Sook Jung Jo; Jae Won Lee; Won Seog Kim
Journal:  Leuk Lymphoma       Date:  2009-05

Review 9.  Impact of interleukin-6 in hematological malignancies.

Authors:  Renate Burger
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

Review 10.  Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms.

Authors:  Eran Elinav; Roni Nowarski; Christoph A Thaiss; Bo Hu; Chengcheng Jin; Richard A Flavell
Journal:  Nat Rev Cancer       Date:  2013-11       Impact factor: 69.800
View more
  6 in total

1.  Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior.

Authors:  Mineui Hong; Taehee Lee; So Young Kang; Suk-Jin Kim; Wonseog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-03-25       Impact factor: 7.842

2.  The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases.

Authors:  Jennifer A Kanakry; Aparna M Hegde; Christine M Durand; Allan B Massie; Amy E Greer; Richard F Ambinder; Alexandra Valsamakis
Journal:  Blood       Date:  2016-01-07       Impact factor: 22.113

3.  Survivin is a prognostic marker and therapeutic target for extranodal, nasal-type natural killer/T cell lymphoma.

Authors:  Li Zhang; Yi Wei; Xiaowei Yan; Na Li; Haolan Song; Li Yang; Yang Wu; Yu-Feng Xi; Hua-Wei Weng; Jian-Hua Li; Edward H Lin; Li-Qun Zou
Journal:  Ann Transl Med       Date:  2019-07

4.  Clinical characteristics and treatment of 69 patients with extranodal natural killer T-cell lymphoma.

Authors:  Yuyan Guo; Enxiao Li; Liping Song; Yinying Wu
Journal:  Mol Clin Oncol       Date:  2016-10-27

5.  Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.

Authors:  Motoko Yamaguchi; Ritsuro Suzuki; Seok Jin Kim; Young Hyeh Ko; Masahiko Oguchi; Naoko Asano; Kana Miyazaki; Yasuhiko Terui; Nobuko Kubota; Takeshi Maeda; Yukio Kobayashi; Jun Amaki; Toshinori Soejima; Bungo Saito; Emiko Shimoda; Noriko Fukuhara; Norifumi Tsukamoto; Kazuyuki Shimada; Ilseung Choi; Takahiko Utsumi; Yasuo Ejima; Won Seog Kim; Naoyuki Katayama
Journal:  Cancer Sci       Date:  2018-04-28       Impact factor: 6.716

6.  Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma.

Authors:  Changqian Bao; Lixia Zhu; Wenbin Qian; Xiujin Ye
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.